Albuminuria during treatment with angiotensin type II receptor blocker is a predictor for GFR decline among non-diabetic hypertensive CKD patients.

ABSTRACT:

Background

Albuminuria is a predictor of disease progression in patients with chronic kidney disease (CKD). However, the ability of proteinuria parameters measured at various time periods to predict renal outcomes is unclear.

Method

This observational cohort study included 165 non-diabetic hypertensive CKD patients who took olmesartan medoxomil. We measured the albuminuria at five different time points (0, 2, 4, 26, and 38 months) and the mean levels. The mean albuminuria levels were calculated during 0-4 months, 0-26 months, and 0-38 months. The renal outcome was defined as a decline in eGFR ≥ 40% during the entire study period.

Result

The albuminuria at five different time points and the mean albuminuria levels were independent risk factors for a worse renal outcome

SUBMITTER: Yu MY 

PROVIDER: S-EPMC6110474 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature